A conserved matrix-centred core links fibrosis across human organs and mouse models
In the authors' words
Fibrosis develops in many organs through different initiating injuries, yet repeatedly engages inflammation, stromal activation and extracellular-matrix remodelling. Whether these recurring features represent a conserved disease programme, and whether commonly used mouse models reproduce it, remain unresolved. We developed ScarX, an R/Shiny workflow that analyses organ-resolved bulk RNA sequencing, identifies directional overlap across tissues, and ranks human-mouse conserved signals while retaining organ-restricted results. Public RNA-sequencing datasets representing fibrotic or fibrosis-associated disease in human heart, kidney, liver and lung were compared with matched mouse injury models. Differential expression was estimated independently within each organ using DESeq2, followed by cross-organ intersection, functional enrichment, matched-organ effect-profile comparison and a human-first conserved modulation (HCM) score that gives greatest weight to the breadth and magnitude of human disease change, adds support for same-direction mouse effects and penalises discordance. In human disease, 202 genes increased and 35 decreased in the same direction across all four organs. Mouse models contained 409 pan-organ increases and 46 decreases. After gene-symbol harmonisation, 25 gene-direction signatures were conserved across all four organs in both species. These included AEBP1, CDH11, COL1A1, COL1A2, COL3A1, COL5A2, COL6A2, EFEMP2, EMILIN1, LOXL1, LOXL2, TGFB2 and VIM. Matched human-mouse effect profiles varied considerably: Spearman rho was 0.42 for kidney, 0.31 for heart, 0.16 for liver and -0.06 for lung. Despite this uneven gene-level fidelity, 62 same-direction pathways were shared across species, led by extracellular-matrix organisation, collagen fibril organisation, cell-substrate adhesion, wound healing and ECM-receptor interaction. The HCM ranking concentrated structural matrix genes near the top but also identified cell-surface, secreted and regulatory candidates. Among the top 500 candidates, 376 carried at least one local tractability annotation. ScarX therefore separates a compact conserved matrix-remodelling core from a much larger organ- and species-dependent response. The results provide a transparent starting point for target and biomarker selection, while also showing why expression conservation alone cannot establish therapeutic dependence.
Appeared: Tuesday, November 17. bioRxiv. Preprint, not yet peer-reviewed.